Effect of second-generation antipsychotics on cognition: current issues and future challenges

References

• Blanchard JJ, Neale JM. The neuropsychological signature of schizophrenia: generalized or differential deficit? Am. J. Psychiatry151(1), 40–48 (1994).
   PubMed Web of Science ®Google Scholar
• Saykin AJ, Shtasel DL, Gur RE et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry51(2), 124–131 (1994).
   PubMed Web of Science ®Google Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology12, 426–445 (1998).
   PubMed Web of Science ®Google Scholar
• Hawkins KA, Keefe RS, Christensen BK et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment study. Schizophr. Res.105(1–3), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr. Res.68(1), 49–63 (2004).
   PubMed Web of Science ®Google Scholar
• Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am. J. Psychiatry156(9), 1336–1341 (1999).
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry153(3), 321–330 (1996).
   PubMed Web of Science ®Google Scholar
• Sevy S, Davidson M. The cost of cognitive impairment in schizophrenia. Schizophr. Res.17(1), 1–3 (1995).
   PubMed Web of Science ®Google Scholar
• Blomqvist AG, Leger PT, Hoch JS. The cost of schizophrenia: lessons from an international comparison. J. Ment. Health Policy Econ.9(4), 177–183 (2006).
   PubMed Web of Science ®Google Scholar
• Hoenberg K, Goetz K. Antipsychotics: Analysis of disease markets and emerging agents. Decision Resources, Inc., Waltham, MA, USA (2006).
   Google Scholar
• Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs14(4), 260–282 (1977).
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Cai JX, Steere JC, Goldman-Rakic PS. Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J. Neurosci.15, 3429–3439 (1995).
   PubMed Web of Science ®Google Scholar
• Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science287, 2020–2022 (2000).
   PubMed Web of Science ®Google Scholar
• Sawaguchi T, Goldman-Rakic PS. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol.71, 515–528 (1994).
   PubMed Web of Science ®Google Scholar
• Ramaekers JG, Louwerens JW, Muntjewerff ND et al. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin. Psychopharmacol.19, 209–221 (1999).
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry157(4), 514–520 (2000).
   PubMed Web of Science ®Google Scholar
• Purdon SE, Woodward N, Lindborg SR, Stip E. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology169(3–4), 390–397 (2003).
   PubMed Web of Science ®Google Scholar
• Bedard MA, Scherer H, Stip E, Cohen H, Rodriguez JP, Richer F. Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain Cogn.43, 31–39 (2000).
   PubMed Web of Science ®Google Scholar
• Reilly JL, Harris MS, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch. Gen. Psychiatry63(11), 1189–1197 (2006).
   PubMed Web of Science ®Google Scholar
• Blyler CR, Gold JM. Cognitive effects of typical antipsychotic treatment: another look. In: Cognition in Schizophrenia. Sharma T, Harvey PD (Eds). Oxford University Press, NY, USA 241–265 (2000).
   Google Scholar
• Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol.98, 367–380 (1989).
   PubMed Web of Science ®Google Scholar
• Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr. Bull.16(3), 477–499 (1990).
   PubMed Web of Science ®Google Scholar
• Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol. Bull.28, 353–366 (1992).
   PubMedGoogle Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry45(9), 789–796 (1988).
   PubMed Web of Science ®Google Scholar
• Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology23(3), 223–239 (2000).
   PubMed Web of Science ®Google Scholar
• Adams B, Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci.18(14), 5545–5554 (1998).
   PubMed Web of Science ®Google Scholar
• Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology28(2), 265–275 (2003).
   PubMed Web of Science ®Google Scholar
• Kargieman L, Santana N, Mengod G, Celada P, Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc. Natl Acad. Sci. USA104(37), 14843–14848 (2007).
   PubMed Web of Science ®Google Scholar
• Jentsch J. Pre-clinical models of cognitive dysfunction in schizophrenia: new avenues to addressing unmet needs. Clin. Neurosci. Res.3, 303–315 (2003).
   Google Scholar
• Abekawa T, Ito K, Nakagawa S, Nakato Y, Koyama T. Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex. Schizophr. Res.101(1–3), 84–94 (2008).
   PubMedGoogle Scholar
• Toua C, Brand L, Mo Ller M, Emsley RA, Harvey BH. The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D(1) receptor binding in rats. Neuroscience DOI:10.1016/j.neuroscience.2009.10.039 (2009) (Epub ahead of print).
   Google Scholar
• Koike H, Ibi D, Mizoguchi H et al. Behavioral abnormality and pharmacologic response in social isolation-reared mice. Behav. Brain Res.202(1), 114–121 (2009).
   PubMed Web of Science ®Google Scholar
• Li N, Wu X, Li L. Chronic administration of clozapine alleviates reversal-learning impairment in isolation-reared rats. Behav. Pharmacol.18(2), 135–145 (2007).
   PubMed Web of Science ®Google Scholar
• Barr AM, Powell SB, Markou A, Geyer MA. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology51(3), 457–465 (2006).
   PubMed Web of Science ®Google Scholar
• Cilia J, Cluderay JE, Robbins MJ et al. Reversal of isolation-rearing-induced PPI deficits by an a7 nicotinic receptor agonist. Psychopharmacology (Berl.)182(2), 214–219 (2005).
   PubMed Web of Science ®Google Scholar
• Kinkead B, Dobner PR, Egnatashvili V, Murray T, Deitemeyer N, Nemeroff CB. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J. Pharmacol. Exp. Ther.315(1), 256–264 (2005).
   PubMedGoogle Scholar
• Abdul-Monim Z, Reynolds GP, Neill JC. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J. Psychopharmacol.17(1), 57–66 (2003).
   PubMedGoogle Scholar
• Amitai N, Semenova S, Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology193(4), 521–537 (2007).
   PubMedGoogle Scholar
• He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-X-sub(L)/Bax ratio in the posterior cingulate cortex in rats. Behav. Brain Res.168(2), 236–242 (2006).
   PubMed Web of Science ®Google Scholar
• He J, Yang Y, Yu Y, Li X, Li XM. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav. Brain Res.172(1), 39–45 (2006).
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Fujita Y, Ishima T et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT-sub(1A) receptors. Eur. Neuropsychopharmacol.18(6), 448–454 (2008).
   PubMedGoogle Scholar
• Dunn MJ, Killcross S. Clozapine, SCH 23390 and α-flupenthixol but not haloperidol attenuate acute phencyclidine-induced disruption of conditional discrimination performance. Psychopharmacology190(4), 403–414 (2007).
   PubMedGoogle Scholar
• Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res.1063(1), 32–89 (2005).
   PubMed Web of Science ®Google Scholar
• He J, Yang Y, Xu H, Zhang X, Li XM. Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology30(8), 1511–1520 (2005).
   PubMed Web of Science ®Google Scholar
• Bardgett ME, Griffith MS, Foltz RF, Hopkins JA, Massie CM, O’Connell SM. The effects of clozapine on delayed spatial alternation deficits in rats with hippocampal damage. Neurobiol. Learning Memory85(1), 86–94 (2006).
   PubMedGoogle Scholar
• Hou Y, Wu CF, Yang JY, Guo T. Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry30(8), 1486–1495 (2006).
   PubMedGoogle Scholar
• Matsumoto M, Shikanai H, Togashi H et al. Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats. Brain Res.1195, 50–55 (2008).
   PubMedGoogle Scholar
• Elsworth JD, Jentseh JD, Morrow BA, Roth RH, Redmond DE Jr. Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine. Neuropsychopharmacology33(3), 491–496 (2008).
   PubMedGoogle Scholar
• Sur C, Mallorga PJ, Wittmann M et al.N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl Acad. Sci. USA100(23), 13674–13679 (2003).
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry36(11), 717–725 (1994).
   PubMed Web of Science ®Google Scholar
• Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry55(Suppl. B), 82–87 (1994).
   PubMed Web of Science ®Google Scholar
• Green MF, Marshall BD Jr, Wirshing WC et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry154(6), 799–804 (1997).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bull.25(2), 233–255 (1999).
   PubMed Web of Science ®Google Scholar
• Green MF. Recent studies on the neurocognitive effects of second-generation antipsychotic medications. Curr. Opin. Psychiatry15(1), 25–29 (2002).
   Google Scholar
• Meltzer HY, McGurk SR. Effect of atypical antipsychotic drugs on cognitive function in schizophrenia. In: The treatment of schizophrenia: status and emerging trends. Brenner HD, Boker W, Genner R (Eds). Hogrefe & Huber Publishers, Ashland, OH, USA, 49–59 (2001).
   Google Scholar
• Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull.25(2), 201–222 (1999).
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol.8(3), 457–472 (2005).
   PubMed Web of Science ®Google Scholar
• Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol. Psychiatry51(12), 969–971 (2002).
   PubMed Web of Science ®Google Scholar
• Perlick D, Stastny P, Katz I, Mayer M, Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am. J. Psychiatry143(2), 230–232 (1986).
   PubMed Web of Science ®Google Scholar
• Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry139(11), 1460–1462 (1982).
   PubMed Web of Science ®Google Scholar
• Purdon SE, Jones BDW, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry57(3), 249–258 (2000).
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry161(6), 985–995 (2004).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Seidman LJ, Christensen BK et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry59(2), 97–105 (2006).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am. J. Psychiatry162(10), 1888–1895 (2005).
   PubMed Web of Science ®Google Scholar
• Thornton AE, Van Snellenberg JX, Sepehry AA, Honer WG. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. Psychopharmacology20(3), 335–346 (2006).
   Google Scholar
• Goldberg TE, Goldman RS, Burdick KE et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch. Gen. Psychiatry64(10), 1115–1122 (2007).
   PubMed Web of Science ®Google Scholar
• Albus M, Hubmann W, Mohr F et al. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur. Arch. Psychiatry Clin. Neurosci.256(7), 442–451 (2006).
   PubMed Web of Science ®Google Scholar
• Hill SK, Reilly JL, Harris MS et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr. Res.113(2–3), 167–175 (2009).
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J. Clin. Psychiatry70(5), 717–729 (2009).
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr. Res.89(1–3), 211–224 (2007).
   PubMed Web of Science ®Google Scholar
• Chapman LJ, Chapman JP. The measurement of differential deficit. J. Psychiatry Res.14, 303–311 (1978).
   PubMed Web of Science ®Google Scholar
• Strauss ME. Demonstrating specific cognitive deficits: a psychometric perspective. J. Abnorm. Psychol.110(1), 6–14 (2001).
   PubMed Web of Science ®Google Scholar
• Dickinson D, Ragland JD, Gold JM, Gur RC. General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol. Psychiatry64(9), 823–827 (2008).
   PubMed Web of Science ®Google Scholar
• Hill SK, Sweeney JA, Hamer RM et al. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J. Int. Neuropsychol. Soc.14(2), 209–221 (2008).
   PubMed Web of Science ®Google Scholar
• Harris MS, Reilly JL, Keshavan MS, Sweeney JA. Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia. Psychol. Med.36(4), 485–494 (2006).
   PubMedGoogle Scholar
• Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry64(6), 633–647 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson M, Galderisi S, Weiser M et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry166(6), 675–682 (2009).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Sweeney JA, Gu H et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry164(7), 1061–1071 (2007).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Harvey PD, Goldberg TE et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr. Res.102(1–3), 108–115 (2008).
   PubMed Web of Science ®Google Scholar
• Dickinson D, Ragland JD, Calkins ME, Gold JM, Gur RC. A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr. Res.85(1–3), 20–29 (2006).
   PubMed Web of Science ®Google Scholar
• Freedman R, Olincy A, Buchanan RW et al. Initial Phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry165(8), 1040–1047 (2008).
   PubMed Web of Science ®Google Scholar
• Liberman RP, Gutkind D, Mintz J et al. Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. Comprehensive Psychiatry43(6), 469–473 (2002).
   PubMedGoogle Scholar
• Manschreck TC, Redmond DA, Candela SF, Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J. Neuropsych. Clin. Neurosci.11(4), 481–489 (1999).
   PubMed Web of Science ®Google Scholar
• Hofer A, Baumgartner S, Bodner T et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur. Psychiatry20(5–6), 395–402 (2005).
   PubMed Web of Science ®Google Scholar
• Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophr. Res.63(1–2), 97–101 (2003).
   PubMed Web of Science ®Google Scholar
• Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry65(7), 932–939 (2004).
   PubMed Web of Science ®Google Scholar
• Perlick DA, Rosenheck RA, Kaczynski R, Collins J, Bingham S. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr. Res.99(1–3), 192–199 (2008).
   PubMed Web of Science ®Google Scholar
• Norman RM, Malla AK, Cortese L et al. Symptoms and cognition as predictors of community functioning: a prospective analysis. Am. J. Psychiatry156(3), 400–405 (1999).
   PubMed Web of Science ®Google Scholar
• Dickerson F, Boronow JJ, Ringel N, Parente F. Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. Schizophr. Res.37(1), 13–20 (1999).
   PubMed Web of Science ®Google Scholar
• Swartz MS, Perkins DO, Stroup TS et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry164(3), 428–436 (2007).
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs18(13), 877–893 (2004).
   PubMed Web of Science ®Google Scholar
• Lipkovich IA, Deberdt W, Csernansky JG, Sabbe B, Keefe RS, Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry9, 44 (2009).
   PubMedGoogle Scholar
• Velligan DI, Kern RS, Gold JM. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr. Bull.32(3), 474–485 (2006).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Keefe RS, Patterson TL, Heaton RK, Bowie CR. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. J. Clin. Exp. Neuropsychol.31(4), 462–471 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol.63(10), 1372–1376 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr. Bull.34(5), 944–961 (2008).
   PubMed Web of Science ®Google Scholar
• Whittington MA, Traub RD, Kopell N, Ermentrout B, Buhl EH. Inhibition-based rhythms: experimental and mathematical observations on network dynamics. Int. J. Psychophysiol.38(3), 315–336 (2000).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci.6(4), 312–324 (2005).
   PubMed Web of Science ®Google Scholar
• Cho RY, Konecky RO, Carter CS. Impairments in frontal cortical γ synchrony and cognitive control in schizophrenia. Proc. Natl Acad. Sci. USA103(52), 19878–19883 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Cho RY, Carter CS et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry165(12), 1585–1593 (2008).
   PubMed Web of Science ®Google Scholar
• Hill SK, Reilly JL, Harris MS, Khine T, Sweeney JA. Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. Schizophr. Bull.34(3), 494–506 (2007).
   PubMedGoogle Scholar
• Light GA, Geyer MA, Clementz BA, Cadenhead KA, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry157(5), 767–771 (2000).
   PubMed Web of Science ®Google Scholar
• Reilly JL, Lencer R, Bishop JR, Keedy S, Sweeney JA. Pharmacological treatment effects on eye movement control. Brain Cogn.68(3), 415–435 (2008).
   PubMedGoogle Scholar
• Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch. Gen. Psychiatry62(2), 127–136 (2005).
   PubMed Web of Science ®Google Scholar
• Keedy SK, Rosen C, Khine T, Rajarethinam R, Janicak PG, Sweeney JA. An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry Res.172(1), 16–23 (2009).
   PubMed Web of Science ®Google Scholar
• Hajos M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol. Sci.27(7), 391–398 (2006).
   PubMed Web of Science ®Google Scholar
• Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajos M. Neurophysiological biomarkers for drug development in schizophrenia. Nat. Rev. Drug Discov.7(1), 68–83 (2008).
   PubMed Web of Science ®Google Scholar
• Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron40(5), 881–884 (2003).
   PubMed Web of Science ®Google Scholar
• Tamminga CA. The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry67(Suppl. 9), 9–13 (2006).
   PubMed Web of Science ®Google Scholar
• Weinberger DR, Egan MF, Bertolino A et al. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry50(11), 825–844 (2001).
   PubMed Web of Science ®Google Scholar
• Bertolino A, Caforio G, Blasi G et al. Interaction of COMT Val108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry161(10), 1798–1805 (2004).
   PubMed Web of Science ®Google Scholar
• Woodward ND, Jayathilake K, Meltzer HY. COMT Val108/158Met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res.90(1–3), 86–96 (2007).
   PubMed Web of Science ®Google Scholar
• Hill SK, Keshavan MS, Thase ME, Sweeney JA. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression. Am. J. Psychiatry161(6), 996–1003 (2004).
   PubMed Web of Science ®Google Scholar
• Reilly JL, Harris MSH, Keshavan MS, Sweeney JA. Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia. Biol. Psychiatry57(2), 145–154 (2005).
   PubMed Web of Science ®Google Scholar
• Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA. Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia. Biol. Psychiatry63(8), 776–783 (2008).
   PubMedGoogle Scholar
• Harris MS, Wiseman CL, Reilly JL, Keshavan MS, Sweeney JA. Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia. Neuropsychopharmacology34(2), 468–476 (2009).
   PubMed Web of Science ®Google Scholar